Botulinum Toxin Market Size

Botulinum Toxin Market Size

Botulinum Toxin Market accounted for about USD 5.9 billion in 2021 and is estimated to grow at 6.9% between 2022 to 2030 owing to the rising demand for minimally invasive or non-invasive surgeries in cosmetology. Furthermore, increasing application in cosmetics surgeries coupled with growing R&D initiatives are expected to expand the therapeutic applications.

For instance, in 2020, according to the America Society of Plastic Surgeons, nearly 10.4 million minimally invasive procedures including facial rejuvenation were performed among females in the U.S. only. Furthermore, increasing R&D initiatives to expand the therapeutic applications of botulinum toxin and rising incidence of aesthetic problems such as lateral canthal lines and crow’s foot are some of the major factors contributing to the growth of botulinum toxin market in the projected timeframe.
 

Botulinum toxin is a neurotoxin protein produced by Clostridium botulinum, a gram-positive anaerobic bacterium. Botulinum toxin prevents the release of the neurotransmitter acetylcholine from axon ending at the neuromuscular junction. This is a non-invasive cosmetic procedure and is used to reduce facial fine lines, forehead creases, wrinkles, crow’s feet among others.
 

The emergence of COVID-19 pandemic has negatively impacted the global market. Various non-emergency surgical and treatment producers as well as non-invasive procedures were delayed owing to the increasing number of COVID-19 cases in 2020. These procedures fall under elective surgical procedures and are not considered as critical lifesaving surgical procedures.
 

For instance, according to the America Society of Plastic Surgeon report, nearly 13% dip were observed in botulinum toxin procedures in 2020. As a result of procedural deferral, various companies witnessed a dip in the sales of botulinum products, thereby negatively impacting the market growth in 2020. However, with the launch of new vaccines and continuation of botulinum toxin surgeries, the market is expected to resume to pre-COVID levels from 2021 and onwards.